Yiqi Yangyin Formula

PreclinicalSmall molecule

Yiqi Yangyin Formula is one of 2 small molecule programs targeting Primary Sjogren's Syndrome. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Primary Sjogren's SyndromeNot yet recruiting

Primary Sjogren's SyndromePreclinical

Not yet recruiting

Competition

Competitive Landscape

1 competitor in Primary Sjogren's Syndrome

#DrugCompanyPhaseTrials

Xeljanz

PPrism Pharmaceuticals

Phase 2

2 2

Yiqi Yangyin Formula

CChina-Japan Friendship Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

N/ANot yet recruiting

Primary Sjogren's Syndrome

NCT07145060

Clinical

Trials by Indication[1]

Primary Sjogren's Syndrome1 trial

A Study of Yiqi Yangyin Formula in the Treatment of Primary Sjogren's Syndrome

Not yet recruiting·—·N/A·NCT07145060·105 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Yiqi Yangyin Formula. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Yiqi Yangyin Formula compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Yiqi Yangyin Formula. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — China-Japan Friendship Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: CChina-Japan Friendship Hospital

Yiqi Yangyin Formula

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Primary Sjogren's Syndrome1 trial

References

Drug Info

Quick Facts

Related News